Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CD73 induces GM-CSF/MDSC-mediated suppression of T cells to accelerate pancreatic cancer pathogenesis
Ryan J. King, Surendra K. Shukla, Chunbo He, et al.
Oncogene (2022) Vol. 41, Iss. 7, pp. 971-982
Open Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance
Mara H. Sherman, Gregory L. Beatty
Annual Review of Pathology Mechanisms of Disease (2022) Vol. 18, Iss. 1, pp. 123-148
Open Access | Times Cited: 206
Nucleotide metabolism: a pan-cancer metabolic dependency
Nicholas J. Mullen, Pankaj K. Singh
Nature reviews. Cancer (2023) Vol. 23, Iss. 5, pp. 275-294
Open Access | Times Cited: 182
GM-CSF: A Double-Edged Sword in Cancer Immunotherapy
Anil Kumar, Adeleh Taghi Khani, Ashly Sanchez Ortiz, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 134
Nanomaterials in tumor immunotherapy: new strategies and challenges
Xudong Zhu, Shenglong Li
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 107
The Good and the Bad: Monocytes’ and Macrophages’ Diverse Functions in Inflammation
Judith Austermann, Johannes Roth, Katarzyna Barczyk‐Kahlert
Cells (2022) Vol. 11, Iss. 12, pp. 1979-1979
Open Access | Times Cited: 101
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors
Johanna C. Bendell, Patricia LoRusso, Michael J. Overman, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 7, pp. 2443-2458
Open Access | Times Cited: 48
Current and future immunotherapeutic approaches in pancreatic cancer treatment
Pooya Farhangnia, Hossein Khorramdelazad, Hamid Nickho, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 34
Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2–SP1–SAT1 axis
Divya Murthy, Kuldeep S. Attri, Surendra K. Shukla, et al.
Nature Cell Biology (2024) Vol. 26, Iss. 4, pp. 613-627
Open Access | Times Cited: 24
MDSC checkpoint blockade therapy: a new breakthrough point overcoming immunosuppression in cancer immunotherapy
Abdulrahman Ibrahim, Nada Mohamady Farouk Abdalsalam, Zihao Liang, et al.
Cancer Gene Therapy (2025)
Open Access | Times Cited: 2
CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer
Célia Jacoberger-Foissac, Isabelle Cousineau, Yacine Barèche, et al.
Cancer Immunology Research (2022) Vol. 11, Iss. 1, pp. 56-71
Open Access | Times Cited: 42
The Immune Regulatory Role of Adenosine in the Tumor Microenvironment
Jianlei Xing, Jinhua Zhang, Jinyan Wang
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14928-14928
Open Access | Times Cited: 31
Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers
Yueming Zhu, Anupam Banerjee, Ping Xie, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 10
Open Access | Times Cited: 9
Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application
Rui Zheng, Xiaobin Liu, Yufu Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 9
CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Erika Y. Faraoni, Kanchan Singh, Vidhi Chandra, et al.
Cancer Research (2023) Vol. 83, Iss. 7, pp. 1111-1127
Open Access | Times Cited: 22
The importance of fusion protein activity in Ewing sarcoma and the cell intrinsic and extrinsic factors that regulate it: A review
April A. Apfelbaum, Emma D. Wrenn, Elizabeth R. Lawlor
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 22
Clinical diagnosis and management of pancreatic cancer: Markers, molecular mechanisms, and treatment options
Chunye Zhang, Shuai Liu, Ming Yang
World Journal of Gastroenterology (2022) Vol. 28, Iss. 48, pp. 6827-6845
Open Access | Times Cited: 20
Targeting the adenosine signaling pathway in macrophages for cancer immunotherapy
Yang Han, Zongliang Zhang, Kai Zhao, et al.
Human Immunology (2024) Vol. 85, Iss. 3, pp. 110774-110774
Closed Access | Times Cited: 4
Listeria-vectored cervical cancer vaccine candidate strains reduce MDSCs via the JAK-STAT signaling pathway
Yunwen Zhang, Lei Yao, Qian Ou, et al.
BMC Biology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 4
Nanoparticles targeting the adenosine pathway for cancer immunotherapy
Kehua Jiang, Jian Wu, Qing Wang, et al.
Journal of Materials Chemistry B (2024) Vol. 12, Iss. 24, pp. 5787-5811
Closed Access | Times Cited: 4
The current understanding of the phenotypic and functional properties of human regulatory B cells (bregs)
Nawara Faiza Ahsan, Stella Lourenço, Dimitra Psyllou, et al.
Oxford Open Immunology (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 4
Development of CD73 Inhibitors in Tumor Immunotherapy and Opportunities in Imaging and Combination Therapy
Chunyang Bi, Jimmy S. Patel, Steven H. Liang
Journal of Medicinal Chemistry (2025)
Open Access
The perspective of targeting cancer cell metabolism: combination therapy approaches
Arezu Karimpur-zahmatkesh, Mohammad Khalaj‐Kondori
Molecular Biology Reports (2025) Vol. 52, Iss. 1
Closed Access
The resurgence of the Adora2b receptor as an immunotherapeutic target in pancreatic cancer
Lincoln N. Strickland, Erika Y. Faraoni, Wei Ruan, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 10
Tumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1/PD-L1 treatment
Kyra Laubach, Tolga Turan, Rebecca Mathew, et al.
Cancer Drug Resistance (2023) Vol. 6, Iss. 3, pp. 611-41
Open Access | Times Cited: 10
ENT1 blockade by CNX-774 overcomes resistance to DHODH inhibition in pancreatic cancer
Nicholas J. Mullen, Ravi Thakur, Surendra K. Shukla, et al.
Cancer Letters (2022) Vol. 552, pp. 215981-215981
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top